Paradromics wins FDA clearance to route its BCI to everyday devices

Paradromics announced on 26 August 2026 that the FDA had approved an expansion of the computing devices its investigational brain-computer interface may drive inside the Connect-One Early Feasibility Study. Participants can now pair compatible internet-connected laptops, tablets and phones through Convey, the company’s user-facing system that translates decoded neural intent into typing and cursor control. The approval covers the class of devices rather than each model, so adding a new one no longer requires its own FDA sign-off.

The change is regulatory rather than surgical. The implant is unchanged: Connexus carries 421 microelectrodes, each thinner than a human hair, reaching about 1.5 mm below the cortical surface to record from individual neurons. What moves is the far end of the link. Until now a participant’s reach stopped at study hardware; the study is evaluating whether the interface can restore communication and computer control for people with severe motor impairment, and most of the computing those people would want to reach sits on their own devices.

Paradromics implanted its first human participant, a Michigan woman with motor neuron disease, at University of Michigan Health in June 2026. Chief clinical officer William J. Marks Jr. framed the expansion around ordinary access rather than capability: much of life now happens online, and a research console is not where it happens.